Supplementary Materialscells-09-00713-s001. induced IFN- expression in T cells within PBMC, and co-stimulated phosphoantigen-induced IFN- expression in T cells. On the other hand, TLR8 ligands potently suppressed T-cell expansion in response to zoledronic acid and phosphoantigen. Purified monocytes secreted large amounts of IL-1 and TNF- when stimulated with TLR8 ligands but simultaneously underwent substantial cell death after 24 h. Conclusions: TLR8 ligand-activated monocytes potently co-stimulate early T-cell activation but failed to provide accessory cell function for in vitro expansion of T cells. 0.05, ** 0.01, *** 0.001 and **** 0.0001. 3. Results We studied the effects of TLR7 and TLR8 ligands on the in vitro activation of human V9V2 T cells using two different read-out systems, i.e., the rapid induction of IFN- production and the cellular expansion in response to stimulation with ZOL and pAg. Since ZOL- and pAg-reactive T cells always co-express V9 and V2, these cells are hereafter LX7101 referred to as V9 or V2, depending on the antibodies used for staining. 3.1. TLR8 but not TLR7 Ligands Stimulate IFN- and Synergize with Phosphoantigen (E)-4-Hydroxy-3-Methyl-but-2-Enyl Pyrophosphate (HMBPP)-Induced IFN- Creation in V2 T Cells PBMC from healthful donors containing normally 2C4% V2 T cells had been activated for 6 to 24 h with 1 g/mL TLR7 ligand Imiquimod, 0.1 g/mL TLR8 ligand TL8-506, or 1 g/mL TLR7/8 ligand Resiquimod in the lack of existence of 10 nM HMBPP. Ethnicities setup in medium just served like a control. Intracellular manifestation of interferon- (IFN-) in V2 T cells was established after 6 and 12 h (pursuing 4 h incubation Rabbit Polyclonal to CLCNKA with monensin), and IFN- within cell tradition supernatants was assessed after 24 h by ELISA. In the lack of TLR HMBPP or ligands, no intracellular IFN- could possibly be recognized (Shape 1a, top row, dark line). Nevertheless, as shown inside a representative test depicted in Shape 1a, Resiquimod and TL8-506, however, not Imiquimod, induced IFN- manifestation in V2 T cells within PBMC in the lack of pAg HMBPP (Shape 1a, top row) currently after 6 h. Furthermore, both LX7101 TLR7/8 and TLR8, however, not TLR7 agonists, also synergized using the HMBPP-triggered IFN- manifestation in V2 T cells after 12 h (Shape 1b, lower row). At the first time stage of 6 h, there is only small induction of IFN- by HMBPP in the lack of TLR ligands LX7101 (dark line in Shape 1a, lower row; equate to dark line in Shape 1a, top row [medium only]). On the other hand, the intracellular expression of IFN- induced by TLR ligands alone was less after 12 h compared to 6 h (Figure 1b, upper row). The intracellular IFN- expression as revealed by flow cytometry corresponded to the levels of secreted IFN- detected in cell culture supernatants by ELISA. As shown in Figure S1a, both TL8-506 and Resiquimod (but not Imiquimod) LX7101 strongly enhanced the levels of IFN- in supernatants of PBMC activated with the V2 T-cell-specific pAg HMBPP. Additional experiments with purified T cells co-cultured with purified monocytes and activated with HMBPP proved that IFN- was indeed produced and secreted by T cells (Figure S1b). Open in a separate window Figure 1 TLR8 and TLR7/8, but not TLR7 ligands, induce and co-stimulate IFN- production in V2 T cells. Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated for 6 (a) or 12 h (b) with 1 g/mL Imiquimod (TLR7 ligand), 0.1 g/mL TL8-506 (TLR8 ligand), or 1 g/mL Resiquimod (TLR7/8 ligand) in the absence (upper panel) or presence (lower panel) of 10 nM HMBPP. Monensin was present during the last 4 h of stimulation. Thereafter, cells were surface stained with anti-CD3 and anti-V2 mAb, and permeabilized before staining with anti-IFN- mAb. A gate was set on V2-positive cells. Black lines indicate the controls (medium only in upper row, medium with HMBPP in lower row). Results are representative of four independent experiments. 3.2. TLR8 Ligands Inhibit Cellular Expansion of V2 T Cells in Response to Zoledronic Acid (ZOL) and HMBPP The above results showed that TLR8 ligands can potently co-stimulate the in vitro activation of V2 T cells as measured by the.